Hydrochlorothiazide,
does it really help with Prevention of clinical and radiologic recurrence of calcium kidney stones?
research showsHydrochlorothiazide is rated F because it failed to prevent clinical or radiologic calcium-stone recurrence while increasing adverse effects. In the 416-participant NOSTONE trial with 2.9 years of median follow-up, no 12.5-, 25-, or 50-mg dose significantly reduced the composite recurrence endpoint versus placebo, and there was no dose response. Hypokalemia, gout, new-onset diabetes, skin allergy, and creatinine elevation were more common. Its antihypertensive efficacy was kept separate from the stone-prevention claim.
ads claimPractice and promotion equate reduced urinary calcium with actual prevention of recurrent stones. The largest direct trial showed that this surrogate did not translate into a lower primary clinical-radiologic recurrence endpoint.
Useful facts when choosing a product
- Hydrochlorothiazide is a prescription diuretic used for hypertension and edema; blood-pressure efficacy is separate from this stone-prevention verdict.
- It can cause hypokalemia, hyponatremia, dehydration, hyperuricemia and gout, higher glucose, and kidney-function changes, requiring laboratory and clinical monitoring.
- It interacts with other antihypertensives, lithium, and nonsteroidal anti-inflammatory drugs, and should not be started or stopped without the prescriber.
What the research actually shows
Dhayat and colleagues randomized 416 recurrent calcium-stone formers in NOSTONE to placebo or hydrochlorothiazide 12.5, 25, or 50 mg and followed them for a median 2.9 years. Primary composite recurrence occurred in 59%, 59%, 56%, and 49%, without a dose response. Symptomatic recurrence was not significantly reduced at any dose. Binary radiologic recurrence was lower at 25 and 50 mg, but new-stone counts and the overall primary endpoint did not establish benefit. Urinary calcium fell, but supersaturation did not consistently decline and adverse effects increased.
Why this is classified as F (12)
The largest direct trial, involving 416 participants over a median 2.9 years, found the primary recurrence endpoint null at all 12.5-to-50-mg doses and increased hypokalemia, gout, new diabetes, and creatinine elevations, giving F with 12 points under the large-null-plus-harm rule.
Counterpoint. Patients already taking it for another indication should not stop solely because of this verdict and should review the treatment purpose and risks with the prescriber.
Rejudgment record. New verdict — Applied the large-null-plus-harm rule because the largest direct NOSTONE trial found the primary recurrence endpoint null at every dose while hypokalemia, gout, new diabetes, and creatinine elevations increased
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of composite clinical and radiologic stone recurrence | F | No NOSTONE dose significantly reduced the primary endpoint versus placebo. |
| Prevention of symptomatic stone recurrence | F | No dose from 12.5 to 50 mg significantly reduced symptomatic recurrence. |
| Actual recurrence prevention through reduced urinary calcium | F | Urinary calcium fell, but the surrogate effect did not translate into improvement in the primary recurrence endpoint. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| NOSTONE trial (Dhayat NA et al.). 2023 | Multicenter double-blind randomized placebo-controlled dose-response trial | 9 | Swiss National Science Foundation and Inselspital | Composite symptomatic or radiologic kidney-stone recurrence | Placebo 59%, 12.5 mg 59%, 25 mg 56%, 50 mg 49%; dose response p=0.66; adverse effects increased | Largest key direct null-plus-harm evidence |
| Bargagli M et al. 2024 review | Review of randomized thiazide stone-prevention trials | Academic review | Clinical and radiologic recurrence and adverse effects | NOSTONE was the largest and null, while earlier trials had substantial methodological limitations | Assessment of reproducibility and limitations of earlier evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Hydrochlorothiazide x prevention of recurrent calcium kidney stones — Evidence Grade F·12. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/hydrochlorothiazide-recurrent-calcium-kidney-stone-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.